field compliance update cdr thomas r. berry, rph fda, investigator ral-rp / atl-do
TRANSCRIPT
![Page 1: FIELD COMPLIANCE UPDATE CDR Thomas R. Berry, RPh FDA, Investigator RAL-RP / ATL-DO](https://reader030.vdocuments.mx/reader030/viewer/2022032705/56649d8d5503460f94a75a8e/html5/thumbnails/1.jpg)
FIELD COMPLIANCE UPDATE
CDR Thomas R. Berry, RPhFDA, Investigator
RAL-RP / ATL-DO
![Page 2: FIELD COMPLIANCE UPDATE CDR Thomas R. Berry, RPh FDA, Investigator RAL-RP / ATL-DO](https://reader030.vdocuments.mx/reader030/viewer/2022032705/56649d8d5503460f94a75a8e/html5/thumbnails/2.jpg)
Information Disclaimer:
The information provided is only intended to be general summary information. It is not intended to take the place of either the written law or regulations.
Opinion Disclaimer:
The comments and opinions expressed are those solely of the presenter. They are not intended to take the place of either the written law or regulations
![Page 3: FIELD COMPLIANCE UPDATE CDR Thomas R. Berry, RPh FDA, Investigator RAL-RP / ATL-DO](https://reader030.vdocuments.mx/reader030/viewer/2022032705/56649d8d5503460f94a75a8e/html5/thumbnails/3.jpg)
CRISSP Score
CDER/ORA Risk-based Inspection Site Selection Prioritization
Larger the score – higher priority “High” priority = “Tier 1” establishments Developed by the Division of Manufacturing
and Product Quality, OC/CDER
![Page 4: FIELD COMPLIANCE UPDATE CDR Thomas R. Berry, RPh FDA, Investigator RAL-RP / ATL-DO](https://reader030.vdocuments.mx/reader030/viewer/2022032705/56649d8d5503460f94a75a8e/html5/thumbnails/4.jpg)
CRISSP Score
Derived from three categories of risk:
Product Process Facility
![Page 5: FIELD COMPLIANCE UPDATE CDR Thomas R. Berry, RPh FDA, Investigator RAL-RP / ATL-DO](https://reader030.vdocuments.mx/reader030/viewer/2022032705/56649d8d5503460f94a75a8e/html5/thumbnails/5.jpg)
FY 06
Approximately 500 establishments identified by CDER as high-risk sites
Includes the following programs:
56002 – Drug Process Inspections (DPI) 56002a – DPI / Small Volume Parenterals 56002b – DPI / Drug Repackers and Relabelers 56002c – DPI / Radioactive Drugs 56002f – API Process Inspections 56002m – DPI / Therapeutic Biological Product Inspections
![Page 6: FIELD COMPLIANCE UPDATE CDR Thomas R. Berry, RPh FDA, Investigator RAL-RP / ATL-DO](https://reader030.vdocuments.mx/reader030/viewer/2022032705/56649d8d5503460f94a75a8e/html5/thumbnails/6.jpg)
CRISSP Score Exclusions
Medical Gas Establishments PADE Inspections Therapeutic biological-only sites Pharmacies Positron-Emission Tomography
![Page 7: FIELD COMPLIANCE UPDATE CDR Thomas R. Berry, RPh FDA, Investigator RAL-RP / ATL-DO](https://reader030.vdocuments.mx/reader030/viewer/2022032705/56649d8d5503460f94a75a8e/html5/thumbnails/7.jpg)
FY 06 – ATL-DO Drug Cadre
Tier 1 = 44 inspections Tier 2 = 133 inspections Pre-Approval Inspections Directed Inspections Complaint Investigations
![Page 8: FIELD COMPLIANCE UPDATE CDR Thomas R. Berry, RPh FDA, Investigator RAL-RP / ATL-DO](https://reader030.vdocuments.mx/reader030/viewer/2022032705/56649d8d5503460f94a75a8e/html5/thumbnails/8.jpg)
FY 06 – ATL-DO Drug Cadre
Drug Surveillance Samples = 29
Collected during GMP Inspections Surveillance vs Compliance
![Page 9: FIELD COMPLIANCE UPDATE CDR Thomas R. Berry, RPh FDA, Investigator RAL-RP / ATL-DO](https://reader030.vdocuments.mx/reader030/viewer/2022032705/56649d8d5503460f94a75a8e/html5/thumbnails/9.jpg)
FACTS
Field Accomplishments and Compliance Tracking System
Creates the assignments for the investigator
Provides firm status and historical investigatory information
![Page 10: FIELD COMPLIANCE UPDATE CDR Thomas R. Berry, RPh FDA, Investigator RAL-RP / ATL-DO](https://reader030.vdocuments.mx/reader030/viewer/2022032705/56649d8d5503460f94a75a8e/html5/thumbnails/10.jpg)
Investigator Example
High Risk GMP Inspections = 8 Downgraded High Risk Inspections = 1 PADE Inspections = 2 District Investigations = 4 Drug Surveillance Samples = 15
![Page 11: FIELD COMPLIANCE UPDATE CDR Thomas R. Berry, RPh FDA, Investigator RAL-RP / ATL-DO](https://reader030.vdocuments.mx/reader030/viewer/2022032705/56649d8d5503460f94a75a8e/html5/thumbnails/11.jpg)
Other Assignments
OCI Investigations = 1 Pharmacy = 1 Seizure = 1 Destruction = 2 Katrina (MS + LA) x 1 month Training x 1 month
![Page 12: FIELD COMPLIANCE UPDATE CDR Thomas R. Berry, RPh FDA, Investigator RAL-RP / ATL-DO](https://reader030.vdocuments.mx/reader030/viewer/2022032705/56649d8d5503460f94a75a8e/html5/thumbnails/12.jpg)
Turbo EIR
Provides more consistency between inspections and investigators
Provides specific citations and examples of violations
Provides information for statistical analysis and identifies potential investigator / FDA / industry trends
![Page 13: FIELD COMPLIANCE UPDATE CDR Thomas R. Berry, RPh FDA, Investigator RAL-RP / ATL-DO](https://reader030.vdocuments.mx/reader030/viewer/2022032705/56649d8d5503460f94a75a8e/html5/thumbnails/13.jpg)
0
20
40
60
80
100
120
140
1105 3585 1358 2027 1361 3603 1112 1883 4391 2009
Top 10 Drug Observations Used in Turbo EIR CY 05CY 05 & CY 04
Turbo Cite ID
Cou
nt
![Page 14: FIELD COMPLIANCE UPDATE CDR Thomas R. Berry, RPh FDA, Investigator RAL-RP / ATL-DO](https://reader030.vdocuments.mx/reader030/viewer/2022032705/56649d8d5503460f94a75a8e/html5/thumbnails/14.jpg)
FDA Top 10 (CY 05)
1. 21 CFR 211.22 (d) – Quality Control Unit Responsibilities and Procedures
2. 21 CFR 211.110 (a) – Process Validation3. 21 CFR 211.100 (b) – Written Production &
Process Controls4. 21 CFR 211.192 – CAPA5. 21 CFR 211.100 (a) – SOPs / Process
Validation
![Page 15: FIELD COMPLIANCE UPDATE CDR Thomas R. Berry, RPh FDA, Investigator RAL-RP / ATL-DO](https://reader030.vdocuments.mx/reader030/viewer/2022032705/56649d8d5503460f94a75a8e/html5/thumbnails/15.jpg)
FDA Top 10 (CY 05)
6. 21 CFR 211.160(b) – Laboratory controls
7. 21 CFR 211.25(a) – Employee Training
8. 21 CFR 211.165(a) – Laboratory Testing & Release
9. 21 CFR 211.180(e)(2) – APRs
10. 21 CFR 211.188 – Batch Production &
Control Records
![Page 16: FIELD COMPLIANCE UPDATE CDR Thomas R. Berry, RPh FDA, Investigator RAL-RP / ATL-DO](https://reader030.vdocuments.mx/reader030/viewer/2022032705/56649d8d5503460f94a75a8e/html5/thumbnails/16.jpg)
Investigator’s Top Ten
1. 21 CFR 211.192 (4) – CAPA
2. 21 CFR 314.80 – PADE Program
3. 21 CFR 211.160 (6) – Laboratory Controls
4. 21 CFR 211.100 (3) – Written production and process controls
5. 21 CFR 211.25 (7) – Employee Training
![Page 17: FIELD COMPLIANCE UPDATE CDR Thomas R. Berry, RPh FDA, Investigator RAL-RP / ATL-DO](https://reader030.vdocuments.mx/reader030/viewer/2022032705/56649d8d5503460f94a75a8e/html5/thumbnails/17.jpg)
Investigator’s Top Ten
6. 21 CFR 211.166 – Stability Program7. 21 CFR 211.67 – Written Procedures Not
Followed for Cleaning & Maintenance of Equipment
8. 21 CFR 211.188 (10) – Batch Production & Control Records
9. 21 CFR 211.22 (1) - Quality Control Unit Responsibilities and Procedures
10. 21 CFR 211.110 (2 +5) – Process Validation
![Page 18: FIELD COMPLIANCE UPDATE CDR Thomas R. Berry, RPh FDA, Investigator RAL-RP / ATL-DO](https://reader030.vdocuments.mx/reader030/viewer/2022032705/56649d8d5503460f94a75a8e/html5/thumbnails/18.jpg)
FDA 483 Disclaimer
This document lists observations made by the FDA representative(s) during the inspection of your facility. They are inspectional observations, and do not represent a final Agency determination regarding your compliance. If you have an objection regarding an observation, or have implemented, or plan to implement, corrective action in response to an observation, you may discuss the objection or action with the FDA representative(s) during the inspection or submit this information to FDA at the address above. If you have any questions, please contact the FDA at the phone number and address listed above.
![Page 19: FIELD COMPLIANCE UPDATE CDR Thomas R. Berry, RPh FDA, Investigator RAL-RP / ATL-DO](https://reader030.vdocuments.mx/reader030/viewer/2022032705/56649d8d5503460f94a75a8e/html5/thumbnails/19.jpg)
Investigator’s Significant Issues
#5 - 21 CFR 211.22(a) - There is no quality control unit.
Must be independent of production.
Must prevent innovative “Marketing Strategies”
![Page 20: FIELD COMPLIANCE UPDATE CDR Thomas R. Berry, RPh FDA, Investigator RAL-RP / ATL-DO](https://reader030.vdocuments.mx/reader030/viewer/2022032705/56649d8d5503460f94a75a8e/html5/thumbnails/20.jpg)
Investigator’s Significant Issues
#4 - 21 CFR 211.110 Control procedures are not established which validate the performance of those manufacturing processes that may be responsible for causing variability in the characteristics of in-process material and the drug product.
The manufacturing and cleaning processes should be validated to assure that each batch of drug product produced meets pre-defined written specifications for identity and strength.
![Page 21: FIELD COMPLIANCE UPDATE CDR Thomas R. Berry, RPh FDA, Investigator RAL-RP / ATL-DO](https://reader030.vdocuments.mx/reader030/viewer/2022032705/56649d8d5503460f94a75a8e/html5/thumbnails/21.jpg)
Investigator’s Significant Issues
#3 - 21 CFR 211.166 Results of stability testing are not used in determining expiration dates.
Must provide data that supports expiration dates.
Must provide data to continuously support the expiration date included in the Application.
![Page 22: FIELD COMPLIANCE UPDATE CDR Thomas R. Berry, RPh FDA, Investigator RAL-RP / ATL-DO](https://reader030.vdocuments.mx/reader030/viewer/2022032705/56649d8d5503460f94a75a8e/html5/thumbnails/22.jpg)
Investigator’s Significant Issues
#2 -21 CFR 211.160(b) Laboratory controls do not include the establishment of scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that drug products conform to appropriate standards of identity, strength, quality and purity.
Test incoming materials and test finished product with scientifically sound methods.
![Page 23: FIELD COMPLIANCE UPDATE CDR Thomas R. Berry, RPh FDA, Investigator RAL-RP / ATL-DO](https://reader030.vdocuments.mx/reader030/viewer/2022032705/56649d8d5503460f94a75a8e/html5/thumbnails/23.jpg)
Investigator’s Significant Issues
#1 - 21 CFR 211.165(f) - Drug products failing to meet established standards, specifications, and quality control criteria are not rejected.
If your active ingredient has not arrived and you receive an immediate order for a product containing that active ingredient, FDA still expects you to wait for the active ingredient to arrive from the supplier and put it in the product.
![Page 24: FIELD COMPLIANCE UPDATE CDR Thomas R. Berry, RPh FDA, Investigator RAL-RP / ATL-DO](https://reader030.vdocuments.mx/reader030/viewer/2022032705/56649d8d5503460f94a75a8e/html5/thumbnails/24.jpg)
Investigator’s Concerns
1. Sterilization – – Pyrogenic reaction case
2. Position Papers –– Explanation of why specific regulation does not
apply to the firm
– Explanation of why the firm has elected not to follow a specific regulation
![Page 25: FIELD COMPLIANCE UPDATE CDR Thomas R. Berry, RPh FDA, Investigator RAL-RP / ATL-DO](https://reader030.vdocuments.mx/reader030/viewer/2022032705/56649d8d5503460f94a75a8e/html5/thumbnails/25.jpg)
Investigator’s Concerns
3. Corrective Actions / Preventative Actions – – Implementations of CAPA
– Review of the potential impacts the event may have on other products / lots.
– Retraining
4. Cleaning & Maintenance of Equipment –– Log Documentation
– Hold times
5. 100 % Visual Inspection of Sterile Products
![Page 26: FIELD COMPLIANCE UPDATE CDR Thomas R. Berry, RPh FDA, Investigator RAL-RP / ATL-DO](https://reader030.vdocuments.mx/reader030/viewer/2022032705/56649d8d5503460f94a75a8e/html5/thumbnails/26.jpg)
Investigator’s Limited Vision
1. High Priority Large Firms – Inspections annually of different product classes.
2. More Cascade Assignments – Inspections resulting from findings at another firm.
3. Compounding Pharmacies – Manufacturing and/or evaluation of how the pharmacy is ensuring the safe and effective use of the compounded product
![Page 27: FIELD COMPLIANCE UPDATE CDR Thomas R. Berry, RPh FDA, Investigator RAL-RP / ATL-DO](https://reader030.vdocuments.mx/reader030/viewer/2022032705/56649d8d5503460f94a75a8e/html5/thumbnails/27.jpg)
Investigator’s Limited Vision
Corporation Responsibility – Holding corporate officers responsible for making sure problems at one facility are not occurring at any of the firm’s other facilities.
![Page 28: FIELD COMPLIANCE UPDATE CDR Thomas R. Berry, RPh FDA, Investigator RAL-RP / ATL-DO](https://reader030.vdocuments.mx/reader030/viewer/2022032705/56649d8d5503460f94a75a8e/html5/thumbnails/28.jpg)
Field Compliance Update
Questions ???